Emily Rhee, | |
7941 Beach Blvd Ste J, Buena Park, CA 90620-1900 | |
(714) 736-6855 | |
Not Available |
Full Name | Emily Rhee |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 7941 Beach Blvd Ste J, Buena Park, California |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1275108276 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208100000X | Physical Medicine & Rehabilitation | PT42537 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Emily Rhee, 333 E Glenoaks Blvd Ste 204, Glendale, CA 91207-2098 Ph: () - | Emily Rhee, 7941 Beach Blvd Ste J, Buena Park, CA 90620-1900 Ph: (714) 736-6855 |
News Archive
Although the death toll is relatively low for people who suffer from traumatic brain injury (TBI), it can have severe, life-long consequences for brain function. TBI can impair a patient's mental abilities, impact memory and behavior, and lead to dramatic personality changes. And long-term medical treatment carries a high economic cost.
More than a quarter-million Medicare beneficiaries are victims of identity theft and hampered in getting health care benefits because the government won't issue new IDs, according to an investigation report released today.
It seems that every time researchers estimate how often a medical mistake contributes to a hospital patient's death, the numbers come out worse. In 1999, the Institute of Medicine published the famous "To Err Is Human" report, which dropped a bombshell on the medical community by reporting that up to 98,000 people a year die because of mistakes in hospitals.
The New York Times: A federal judge Monday threw out two patents on human genes that are linked to breast and ovarian cancer. "The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property."
NPS Pharmaceuticals, Inc. today announced the sale of its royalty rights from sales of REGPARA® (cinacalcet HCl) to a fund managed by DRI Capital, Inc., (Fund) for $38.4 million. Royalties in excess of cumulative royalties of $96 million or 2.5 times the upfront purchase price have been retained by NPS.
› Verified 2 days ago